De-intensification of basal-bolus therapy by replacing prandial insulin with once-weekly subcutaneous semaglutide in individuals with well-controlled type 2 diabetes: A single-centre, open-label randomised trial (TRANSITION-T2D).

ABSTRACT:

Aims

The study aims to examine the outcome of replacement of prandial insulin with once-weekly subcutaneous semaglutide in people with type 2 diabetes reasonably controlled on multiple daily insulin injections (MDI).

Materials and methods

This single-centre, randomised, open-label trial enrolled a statistically predetermined sample of 60 adults with HbA1c ≤7.5% (58 mmol/mol) receiving MDI, with a total daily dose (TDD) ≤120 units/day. Participants were assigned 2:1 to subcutaneous semaglutide 1.0 mg plus insulin degludec, or to continue MDI. The primary outcome was percentage of subjects maintaining HbA1c ≤7.5% (58 mmol/mol) at Week 26.

Results

At Week 26, 90% of semaglutide and 75% of MDI subjects maintained HbA_1c ≤7.5% (≤58 mmol/mol) (p = 0.18). Mean chan

SUBMITTER: Rodriguez P 

PROVIDER: S-EPMC11701190 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature